Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
12
pubmed:dateCreated
2004-11-19
pubmed:abstractText
We demonstrated that highly active antiretroviral therapy (HAART) increases the toxic effect of cyclophosphamide, vincristine, doxorubicin (DOX) and prednisone (CHOP) in HIV-patients with non-Hodgkin's lymphoma (NHL). To ascertain the cause of increased toxicity, we investigated the pharmacokinetics of DOX in HIV-patients with NHL treated with CHOP with and without HAART.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1805-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15550586-Adult, pubmed-meshheading:15550586-Antibiotics, Antineoplastic, pubmed-meshheading:15550586-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15550586-Antiretroviral Therapy, Highly Active, pubmed-meshheading:15550586-Area Under Curve, pubmed-meshheading:15550586-Cross-Over Studies, pubmed-meshheading:15550586-Cyclophosphamide, pubmed-meshheading:15550586-Doxorubicin, pubmed-meshheading:15550586-Drug Interactions, pubmed-meshheading:15550586-Female, pubmed-meshheading:15550586-HIV Infections, pubmed-meshheading:15550586-Humans, pubmed-meshheading:15550586-Lymphoma, AIDS-Related, pubmed-meshheading:15550586-Lymphoma, Non-Hodgkin, pubmed-meshheading:15550586-Male, pubmed-meshheading:15550586-Middle Aged, pubmed-meshheading:15550586-Prednisone, pubmed-meshheading:15550586-Vincristine
pubmed:year
2004
pubmed:articleTitle
Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
pubmed:affiliation
Experimental and Clinical Pharamcology Unit, National Cancer Institute, Aviano, Italy. gtoffoli@cro.it
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't